May 9, 2012. Kuala Lumpar – Ceva Animal Health Asia Pacific held the first “Hatchery Vaccination Summit Asia - The Future is Today” on Jeju Island, South Korea April 26 - 27, 2012. The conference attracted more than 150 professionals from 10 different Asian countries who collectively produce over three billion broilers.

"Creating platforms such as this to share experiences in hatchery vaccination is vital if we are to successfully meet the needs of future generations for safe poultry protein,” said Mr. Ruud Aerdts, Director of Ceva Animal Health Asia Pacific, when opening the conference. “Ceva is committed to continue investing in developing innovative hatchery solutions that will make poultry production easier and more effective."

Mr. Gordon Butland from G&S Agriconsultants analyzed the “Effects of the current financial crisis on the global poultry industry” and stressed the challenges that the Asian poultry industry will face to remain competitive in the coming years.

Today 60% of all broilers are vaccinated in the hatchery; a figure that Ceva expects will reach 80% to 90% over the next 5 years. This trend will be driven both by innovation in vaccine technology and through improved methods and services surrounding vaccination.

The summit focused both on the practical aspects of hatchery management, as well as highlighting the changes that new vaccines will bring to current programmes. Mr. Pramote Rutavepol, Vice-President of Broiler Operation – Charoen Pokphand Foods, emphasized the benefits that hatchery vaccination brings to their operations over traditional farm vaccination. He said, “We get more uniform titres and therefore better protection. At the same time, there is less stress on the birds helping us to reduce antibiotic use, save on labour costs and perhaps most importantly reduced condemnation rates.” Mr. Pramote stressed that with advances in the technology of production units, one person was now able to manage up to 200,000 broilers, meaning that on-farm vaccination will no longer fit with this model.

Ceva is the world leader in poultry vector vaccine technology with the highest number of vaccines registered globally (14) and an ambitious scientific program that will result in further benefits to poultry producers from this novel technology. Dr Moto Esaki, Senior Chief Researcher at Ceva Japan and a member of the global team that developed these vaccines, explained the huge potential of the new products.

Dr. Yannick Gardin, Ceva’s Director of Biology Innovation Strategy, outlined the impressive results obtained by two of the vector vaccines: Vectormune® HVT-NDV (Newcastle disease) and Vectormune® HVT-AIV (Avian Influenza vaccine), commenting, “Ceva’s new Vectormune® ND and AI vaccines are not only an evolution compared to conventional vaccines. They are a revolution!”

-Ends-

About Ceva Santé Animale: Ceva, or Ceva Santé Animale, is an international veterinary health company that focuses on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, poultry, ruminant and swine.

Visit www.ceva.com.

For further information and images or to organize meetings and interviews contact:
Martin Mitchell
Group Communications Director
Tel: +33 (0)5 57 55 40 80
martin.mitchell@ceva.com